treatment of adult male patients with advanced hormonedependent prostate cancer - patients without spinal metastases
Degarelix should be recommended/initiated by specialist services– AMBER0 recommendation.
Degarelix is recommended as an alternative to lutenising hormone releasing hormone agonists (LHRH) for treatment of adult male patients with advanced hormone-dependent prostate cancer without spinal metastases ONLY in the following circumstances:
- where LHRH analogues or concomitant anti-androgens are contra-indicated.
- in patients on androgen deprivation therapy who have a significant cardiac history/severe cardiac disease.
- very significant, symptomatic metastatic disease, and locally advanced disease to shrink the metastases.
- impending bladder outlet obstruction due to prostate cancer.
Amber level 0
Reason for decision: